DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma

Early Phase 1

Terminated

Conditions: T-Cell Lymphoma
Relapsed T-Cell Lymphoma
Refractory T-Cell Lymphoma

Interventions: Drug: PEG-L-asparaginase
Drug: Dexamethasone acetate

First Posted Date: 2013-06-17

Last Posted Date: 2017-03-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2

Registration Number: NCT01878708

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Device: Multiparametric MRI
Procedure: Prostate biopsy

First Posted Date: 2013-05-21

Last Posted Date: 2023-05-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 101

Registration Number: NCT01858688

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

iCAT for Recurrent/Refractory/HR Solid Tumors

Completed

Conditions: Wilms Tumor
Sarcoma
Neuroblastoma
Pediatric Solid Tumor

First Posted Date: 2013-05-15

Last Posted Date: 2015-02-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 101

Registration Number: NCT01853345

Locations: 🇺🇸
Children's National Medical center, Washington, District of Columbia, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab
Drug: Trastuzumab emtansine
Drug: Paclitaxel

First Posted Date: 2013-05-15

Last Posted Date: 2024-07-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 512

Registration Number: NCT01853748

Locations: 🇺🇸
Rex Cancer Center, Raleigh, North Carolina, United States
🇺🇸
Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Memorial Sloan Kettering Cancer Center Westchester, Harrison, New York, United States

and more 75 locations

Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Behavioral: Personal Patient Profile - Prostate (P3P)
Behavioral: Standard prostate cancer information websites

First Posted Date: 2013-05-03

Last Posted Date: 2018-01-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 392

Registration Number: NCT01844999

Locations: 🇺🇸
Kaiser Permanente - Souther California, Downey, California, United States
🇺🇸
Kaiser Permanente - Southern California, Los Angeles, California, United States
🇺🇸
Emory Healthcare, Atlanta, Georgia, United States

and more 1 locations

The PediQUEST Study: Evaluation of Pediatric Quality of Life and Evaluation of Symptoms Technology

Not Applicable

Completed

Conditions: Pediatric Neoplasm
Quality of Life
Outcome Assessment
Palliative Care

Interventions: Other: Routine Data collection
Other: Feedback of patient-reported outcomes

First Posted Date: 2013-04-24

Last Posted Date: 2013-04-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 104

Registration Number: NCT01838564

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸
Children's Hospital of Philapdelphia, Philadelphia, Pennsylvania, United States

and more 1 locations

Tivozanib + Gemcitabine in Metastatic RCC

Phase 2

Withdrawn

Conditions: Renal Cell Carcinoma

Interventions: Drug: Tivozanib
Drug: Gemcitabine

First Posted Date: 2013-04-17

Last Posted Date: 2013-06-19

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT01834183

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 1 locations

Sunitinib in Never-Smokers With Lung Adenocarcinoma

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Sunitinib

First Posted Date: 2013-04-11

Last Posted Date: 2018-10-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 13

Registration Number: NCT01829217

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States

and more 1 locations

Eribulin in HER2 Negative Metastatic BrCa

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Eribulin

First Posted Date: 2013-04-10

Last Posted Date: 2024-11-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 83

Registration Number: NCT01827787

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
DF/BWCC at Milford Regional Cancer Center, Milford, Massachusetts, United States
🇺🇸
South Shore Hospital, Weymouth, Massachusetts, United States

and more 4 locations

NIR-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer

Phase 1

Completed

Conditions: Esophageal Cancer

Interventions: Drug: Near Infrared Imaging

First Posted Date: 2013-03-11

Last Posted Date: 2017-12-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT01808417

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy